Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients [0.03%]
阿帕替尼治疗晚期软组织肉瘤的疗效和安全性：一项45例患者的开放性非随机单中心试验
Yao Weitao,Wu Fangxing,Cai Qiqing et al.
Yao Weitao et al.
Sarcoma is a rare tumor with more than 50 histologic subtypes. Patients with advanced sarcoma have a poor prognosis. The aim of this study was to evaluate the efficacy and safety of apatinib, an oral vascular endothelial growth factor recep...
Clinical Trial
Anti-cancer drugs. 2019 Aug;30(7):e0778. DOI:10.1097/CAD.0000000000000778 2019
Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel [0.03%]
雷莫卢单抗联合紫杉醇治疗胃癌肺转移患者效果不佳
Giandomenico Roviello,Silvia P Corona,Andrea G Multari et al.
Giandomenico Roviello et al.
The aim of this report is to investigate the activity of ramucirumab in combination with paclitaxel in patients with metastatic gastric cancer (GC) and lung metastases. We retrospectively reviewed clinical data from patients with GC treated...
Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution [0.03%]
brigatinib治疗二线及以上ALK重排非小细胞肺癌的疗效观察——单中心真实世界数据回顾性分析
Maximilian Hochmair,Christoph Weinlinger,Sophia Schwab et al.
Maximilian Hochmair et al.
The second-generation ALK tyrosine kinase inhibitor brigatinib has recently been approved in the European Union for use after crizotinib treatment in patients with EML4-ALK-rearranged lung cancer. In the current study, brigatinib was invest...
Clinical Trial
Anti-cancer drugs. 2019 Aug;30(7):e0787. DOI:10.1097/CAD.0000000000000787 2019
ADAM8 promotes chondrosarcoma cell migration and invasion by activating the NF-κB/MMP-13 signaling axis [0.03%]
ADAM8通过激活NF-κB/MMP-13信号轴促进软骨肉瘤细胞迁移和侵袭
Yan Liu,Zhe-Hai Li,Lan Zhang et al.
Yan Liu et al.
ADAM8 is reported to promote extracellular matrix degradation to provide conditions for tumor metastasis. However, the underlying mechanism of ADAM8 in modulating chondrosarcoma (CHS) metastasis remains unclear. We used two human CHS cell l...
Casein kinase 1α-dependent inhibition of Wnt/β-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity [0.03%]
依赖于酪蛋白激酶1α对Wnt/β-连环蛋白的选择性靶向抑制仅针对鼻咽癌并增加化疗敏感性
Jiangping Li,Yan Jiang,Pengju Wang et al.
Jiangping Li et al.
Pyrvinium tosylate (PT) is an anthelminthic drug that has recently been shown to suppress various human cancers. However, whether PT is effective in nasopharyngeal carcinoma (NPC) has not been determined to date. In this work, we show the s...
Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor [0.03%]
EZH2通过胰岛素样生长因子1受体促进肝癌索拉非尼耐药性
Jing Hu,Jing Zhang,Feifei Sun et al.
Jing Hu et al.
Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) is the core component of polycomb repressive complex 2 and is overexpressed in several types of solid malignancies. It has been reported that EZH2 contributes to sorafenib res...
Sevoflurane downregulates insulin-like growth factor-1 to inhibit cell proliferation, invasion and trigger apoptosis in glioma through the PI3K/AKT signaling pathway [0.03%]
异氟醚通过PI3K/AKT信号通路下调胰岛素样生长因子-1抑制胶质瘤细胞增殖、侵袭并诱导凋亡
Cao Gao,Xiao-Feng He,Qing-Rong Xu et al.
Cao Gao et al.
Sevoflurane is a new type of inhalation anesthetic used widely in the clinic. It has the characteristics of rapid induction, rapid recovery, and less irritative to the airway. Studies have shown that sevoflurane can affect the invasion and ...
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer [0.03%]
帕妥珠单抗与曲妥珠双药联合在HER2阳性早期乳腺癌中国患者中的药物代谢动力学研究
Yang Luo,Wei Li,Zefei Jiang et al.
Yang Luo et al.
In the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G), pertuzumab added to trastuzumab and chemotherapy significantly improved invasive disease-free survival as adjuvant treatment for patients with HER2-positive early breast cancer...
Randomized Controlled Trial
Anti-cancer drugs. 2019 Sep;30(8):866-872. DOI:10.1097/CAD.0000000000000808 2019
Oral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient [0.03%]
口服小剂量环磷酰胺治疗晚期卵巢癌：一位老年体弱患者的长期临床缓解案例
Michela Villa,Daniela Attianese,Massimo Petracchini et al.
Michela Villa et al.
Elderly patients with ovarian cancer are an increasing population and many of them are frailty with an increased risk of postoperative complications, chemotherapy intolerance and mortality. Metronomic chemotherapy is the chronic administrat...
Cheng Zhang,Han Yao,Pei-Yang Kong et al.
Cheng Zhang et al.
Pegylated liposomal doxorubicin (Peg-Dox) treatment resulted in a good outcome for patients with lymphoma and multiple myeloma, with reduced cardiotoxicity and an improved pharmacokinetic profile when compared to those of conventional doxor...